6335-15-5

Basic information

• Product Name: bis(2-chlorophenyl)methanol
• CAS NO: 6335-15-5
• Molecular Formula: C₁₃H₁₀Cl₂O
• Molecular Weight: 253.1239
• Mol File: 6335-15-5.mol

Chemical Properties

• Boiling Point: 370.2°C at 760 mmHg
• Flash Point: 141.6°C
• Density: 1.325g/cm³
• Vapor Pressure: 3.89E-06mmHg at 25°C
• Refractive Index: 1.617
• CAS DataBase Reference: bis(2-chlorophenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: bis(2-chlorophenyl)methanol(6335-15-5)
• EPA Substance Registry System: bis(2-chlorophenyl)methanol(6335-15-5)

Safety Data

• Hazardous Substances Data: 6335-15-5(Hazardous Substances Data)

Upstream product

• 36692-27-0 2-chlorophenylmagnesium bromide 
• 89-98-5 2-chloro-benzaldehyde 
• 5293-97-0 2,2'-dichlorobenzophenone 
• 615-41-8 2-iodochlorobenzene 
• 694-80-4 2-bromo-1-chlorobenzene 

Downstream Products

• 109395-72-4 2,2'-dichloro-benzophenone-(2,4-dinitro-phenylhydrazone) 
• 200868-49-1 bis-(2-chlorophenyl)-bromomethane 
• 439094-10-7 bis-(2-chlorophenyl)methylamine 
• 791119-72-7 1-benzyl-4-(2,2'-dichlorobenzhydryloxy)piperidine 
• 720674-03-3 C₂₆H₁₈Cl₄O 
• 7498-78-4 acetic acid-(2,2'-dichloro-benzhydryl ester) 
• 5293-97-0 2,2'-dichlorobenzophenone 

Relevant articles and documents

Synthesis, Structure, Reactivity, and Catalytic Activity of Cyclometalated (Phosphine)- and (Phosphinite)ruthenium Complexes

Reactions of naphthyl- and o-methylphenyl-substituted phosphines with [RuCl2(p-cymene)]2 resulted in the corresponding phosphine-substituted ruthenium dichlorides (1a,b and 3). When the reactions of aryl-substituted phosphines or pho

Pd-catalyzed enantioselective C-H iodination: Asymmetric synthesis of chiral diarylmethylamines

An enantioselective C-H iodination reaction using a mono-N-benzoyl- protected amino acid has been developed for the synthesis of chiral diarylmethylamines. The reaction uses iodine as the sole oxidant and proceeds at ambient temperature and under air.

3 -MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS

Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted; R

Process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols

The present invention relates to a process for preparing substituted 8-azabicyclo[3.2.1]octan-3-ols having the structural formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R is benzyl, R5-benzyl, allyl, —C(O)R6, —C(O)OR8 or —CH(R7)2; R1 is optionally substituted aryl or optionally substituted heteroaryl; and R5, R6, R7 and R8 are as defined in the specification; comprising a) reacting an amine of formula II [in-line-formulae]R—NH2??II [/in-line-formulae] with 2,5-dimethoxytetrahydrofuran or HC(O)(CH2)2C(O)H, and C(O)(CH2C(O)OR4)2, wherein R4 is H or alkyl, to obtain a compound of formula III b) reacting a compound of formula III with I-R1, alkyl lithium, and optionally a lithium salt, to obtain a compound of formula I; and c) optionally converting a compound of formula I wherein R is benzyl, R5-benzyl, allyl, —C(O)R6 or —C(O)OR6 to a compound of formula I wherein R is —CH(R7)2. Intermediates in the process are also claimed.

AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS

Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR16C(O)R17;Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.

AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS

Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors such as obesity: Formuila (I) wherein: R1 and R2 are independently selected from aryl; and R3 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, wherein at least one of R1 and R2 has a non-hydrogen substituent in the ortho-position(s) thereof relative to the point of attachment to the [-CH-0-] group.